Cross-protective vaccine efficacy of the bivalent HPV vaccine against HPV31 is associated with humoral immune responses

Safaeian, Mahboobeh; Kemp, Troy J.; Pan, David Yuanji; Porras, Carolina; Rodríguez, Ana Cecilia; Schiffman, Mark; Cortés, Bernal; Katki, Hormuzd A.; Wacholder, Sholom; Schiller, John T.; González, Paula; Penrose, Kerri J.; Lowy, Douglas R.; Quint, Wim; Doorn, Leen–Jan van; Herrero, Rolando; Hildesheim, Allan; Pinto, Lígia A.

doi:10.4161/hv.24340

Cited by 35 publications

(29 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…7,15 For example, Cervarix Ò has shown approximately 77.1% cross-protection against HPV-31, 23 while Gardasil Ò has only shown significant efficacy against HPV-31 persistent infection. 24 The induction of low level HPV-58 neutralizing titers following Gardasil Ò administration is also in agreement with a previous report 25 but remains difficult to interpret, as this vaccine does not seem to show cross-protection against HPV-58.…”

Section: Discussionmentioning

confidence: 99%

“…4 There are 2 licensed HPV vaccines (HPV-16/18/6/11, Gardasil Ò and HPV-16/18, Cervarix Ò ) with excellent efficacy against vaccine types and some degree of protection against HPV-16 and HPV-18 phylogenetically related non-vaccine types. [5][6][7][8] Both HPV vaccines are virus-like particles (VLPs) based on the major HPV capsid protein L1. Antigenically the vaccines are very similar but are produced in different systems and contain different adjuvants.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Comparison of adaptive and innate immune responses induced by licensed vaccines for human papillomavirus

Herrin

Coates

Costner

et al. 2014

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Comparison of adaptive and innate immune responses induced by licensed vaccines for human papillomavirus

Herrin

Coates

Costner

et al. 2014

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

“…Diferentes esquemas de vacunación no parecen alterar en gran medida la respuesta inmune general (105), dado que existe cierta evidencia de que, al menos, existe una protección parcial, después de una o dos dosis de la vacuna contra el VPH (106). A su vez, existe una buena correlación entre la protección cruzada frente a 3vHPV y los títulos de anticuerpos después de la inmunización por 2vHPV (107). La administración conjunta de vacunas contra el VPH con otras vacunas importantes, como hepatitis A, hepatitis B, vacuna meningocócica o tétanos, difteria y tosferina no ha presentado respuestas inmunes inferiores al VPH en comparación con la vacuna del VPH aislada (108).…”

Section: Según El Servicio De Medicina Preventiva Y Gestión De Calidaunclassified

Naprotecnología: ciencia y persona en la infección por el virus del papiloma humano (VPH) en mujeres y preadolescencentes

et al. 2017

View full text Add to dashboard Cite

En la actualidad hay suficiente evidencia científica que relaciona directamente adquisición, exposición y prevalencia del virus del papiloma humano (VPH) con el cáncer del cuello de uterino. Por ello, el artículo aborda el VPH en la mujer teniendo en cuenta la naprotecnología, que permite conjugar evidencia científica y planteamientos éticos. Se busca que se tengan en cuenta tanto el aspecto biológico de la sexualidad como la capacidad de hacerse persona en su núcleo sexual. De ahí que se analicen programas dirigidos a la educación sexual, basados tanto en la prevención sanitaria como en la antropología de la sexualidad, y apoyados por las instituciones familiares, que han demostrado una mejor acogida ante los riesgos de las enfermedades de transmisión sexual, y entre ellas la infección por el VPH.

show abstract

“…HPV vaccine type-specific protection is assumed to be mediated by L1-neutralizing antibodies, which can be detected in the serum and cervicovaginal secretions of vaccinees (16,(19)(20)(21)(22). The role of L1-neutralizing antibodies in mediating cross-protection is less clear, although a recent study reported an association between the presence of HPV31 cross-neutralizing antibodies and a reduced risk of HPV31 infection (23). Next-generation L1 VLPbased vaccines aim to extend the breadth of coverage by incorporating an increased number of L1 VLPs (24,25).…”

mentioning

confidence: 96%

Naturally Occurring Capsid Protein Variants of Human Papillomavirus Genotype 31 Represent a Single L1 Serotype

Bissett

Godi

Fleury

et al. 2015

J Virol

View full text Add to dashboard Cite

We investigated naturally occurring variation within the major (L1) and minor (L2) capsid proteins of oncogenic human papillomavirus (HPV) genotype 31 (HPV31) to determine the impact on capsid antigenicity. L1L2 pseudoviruses (PsVs) representing the three HPV31 variant lineages, variant lineages A, B, and C, exhibited comparable particle-to-infectivity ratios and morphologies. Lineage-specific L1L2 PsVs demonstrated subtle differences in susceptibility to neutralization by antibodies elicited following vaccination or preclinical L1 virus-like particle (VLP) immunization or by monoclonal antibodies; however, these differences were generally of a low magnitude. These data indicate that the diagnostic lineage-specific single nucleotide polymorphisms within the HPV31 capsid genes have a limited effect on L1 antibody-mediated neutralization and that the three HPV31 variant lineages belong to a single L1 serotype. These data contribute to our understanding of HPV L1 variant antigenicity. IMPORTANCEThe virus coat (capsid) of the human papillomavirus contains major (L1) and minor (L2) capsid proteins. These proteins facilitate host cell attachment and viral infectivity and are the targets for antibodies which interfere with these events. In this study, we investigated the impact of naturally occurring variation within these proteins upon susceptibility to viral neutralization by antibodies induced by L1 VLP immunization. We demonstrate that HPV31 L1 and L2 variants exhibit similar susceptibility to antibody-mediated neutralization and that for the purposes of L1 VLP-based vaccines, these variant lineages represent a single serotype. Human papillomaviruses (HPVs) have a double-stranded DNA genome of approximately 8 kb which is replicated via host cell polymerases with an error rate of ca. 2 ϫ 10 Ϫ8 base substitutions per site per year (1), substantially lower than that found in the majority of single-stranded RNA viruses (ca. 1 ϫ 10 Ϫ3 base substitutions per site per year) (2). Despite the low evolutionary rate of the HPV genome, variants have arisen over time, leading to the generation of distinct intragenotype lineages classified by a sequence difference of 1 to 10% across the whole genome (3). The single nucleotide polymorphisms (SNPs) that allow segregation of these variants into distinct lineages can be found in each gene/ region, with the highest number accumulating in the noncoding regions (NCR1, NCR2, and URR) and the lowest number accumulating in structural (L1 and L2) genes (4).The HPV structural genes encode the major (L1) and minor (L2) proteins that form the nonenveloped icosahedral viral capsid, which comprises 72 pentameric L1 capsomers, and each capsomer has an upper estimate of one L2 protein (5). The L1 protein mediates attachment to host cells (6), while the L2 protein is essential for subsequent viral infectivity (7).The humoral immune response following natural HPV infection predominately targets conformational epitopes on the surface-exposed loop regions of the L1 protein (8, 9). Seroconvers...

show abstract

Cross-protective vaccine efficacy of the bivalent HPV vaccine against HPV31 is associated with humoral immune responses

Abstract: High HPV16 levels and avidity, and the ability to neutralize HPV31 were associated with protection against newly detected HPV31 infections, suggesting that the partial VE demonstrated for HPV31 is likely to be mediated at least in part through antibodies induced by HPV16/18 vaccination.

Cited by 35 publications

References 23 publications

Comparison of adaptive and innate immune responses induced by licensed vaccines for human papillomavirus

Comparison of adaptive and innate immune responses induced by licensed vaccines for human papillomavirus

Naprotecnología: ciencia y persona en la infección por el virus del papiloma humano (VPH) en mujeres y preadolescencentes

Naturally Occurring Capsid Protein Variants of Human Papillomavirus Genotype 31 Represent a Single L1 Serotype

Contact Info

Product

Resources

About